The effect size for each of the patient-reported outcomes from hospitalisation to 7, 14, 21, 28, 56 and 84 days
Patient-reported outcomes | Days 1–7 | Days 1–14 | Days 1–21 | Days 1–28 | Days 1–56 | Days 1–84 | ||||||
n | Effect size | n | Effect size | n | Effect size | n | Effect size | n | Effect size | n | Effect size | |
EXACT total score | 32 | −1.14 | 31 | −1.40 | 32 | −1.09 | 33 | −1.25 | 30 | −1.29 | 27 | −1.18 |
Breathlessness domain score | 33 | −0.91 | 32 | −1.08 | 32 | −0.75 | 33 | −0.87 | 30 | −0.89 | 27 | −0.74 |
Cough and sputum domain score | 33 | −0.70 | 32 | −1.21 | 32 | −1.03 | 33 | −0.97 | 30 | −1.10 | 27 | −1.14 |
Chest symptoms domain score | 33 | −1.10 | 32 | −1.50 | 32 | −1.12 | 33 | −1.29 | 30 | −1.44 | 27 | −1.26 |
CAT score | 33 | −1.04 | 32 | −1.36 | 32 | −1.24 | 33 | −1.31 | 30 | −1.28 | 27 | −1.17 |
SGRQ total score | 31 | −0.24 | 30 | −0.59 | 30 | −0.47 | 30 | −0.51 | 27 | −0.59 | 25 | −0.52 |
SGRQ symptoms | 31 | 0.18 | 30 | −0.14 | 30 | −0.05 | 30 | −0.23 | 28 | −0.47 | 26 | −0.38 |
SGRQ activity | 31 | −0.32 | 30 | −0.56 | 30 | −0.37 | 30 | −0.37 | 27 | −0.45 | 25 | −0.38 |
SGRQ impact | 31 | −0.24 | 30 | −0.59 | 30 | −0.56 | 31 | −0.66 | 28 | −0.61 | 26 | −0.59 |
Hyland Scale score | 31 | 0.77 | 30 | 0.96 | 28 | 0.86 | 30 | 0.78 | 26 | 0.91 | 25 | 0.81 |
D-12 total score | 28 | −0.54 | 29 | −0.90 | 28 | −0.76 | 29 | −0.76 | 27 | −0.82 | 24 | −0.75 |
D-12 physical score | 29 | −0.57 | 29 | −1.04 | 28 | −0.86 | 29 | −0.85 | 27 | −0.99 | 24 | −0.86 |
D-12 affective score | 29 | −0.50 | 30 | −0.71 | 29 | −0.60 | 30 | −0.62 | 28 | −0.58 | 26 | −0.61 |
Data are presented as mean±SD.
CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; D-12, Dyspnoea-12; EXACT, Exacerbations of Chronic Pulmonary Disease Tool; SGRQ, St George’s Respiratory Questionnaire.